Medtronic plc

For the period ended Apr 25, 2025. Filed Jun 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jun 20, 2025

MDT$101.59-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits and Financial Statement Schedules

(a)	1. Financial Statement Schedule
	Schedule II. Valuation and Qualifying Accounts — fiscal years ended April 25, 2025, April 26, 2024, and April 28, 2023.

MEDTRONIC PLC AND SUBSIDIARIES

SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

(in millions)

Additions · Deductions
Balance atBeginning ofFiscal Year · Charges to Income · Charges to Other Accounts · Other Changes (Debit) Credit · Balanceat End ofFiscal Year
Allowance for doubtful accounts and credit losses:
Fiscal year ended April 25, 2025	$173		$123		$—	$(97)(a)	$199
Fiscal year ended April 26, 2024	176		90		—	(93)(a)	173
Fiscal year ended April 28, 2023	230		73		—	(127)(a)	176
Deferred tax valuation allowance:
Fiscal year ended April 25, 2025	$13,271		$151		$9(d)	$(195)(c)	$12,668
					(567)(e)
Fiscal year ended April 26, 2024	11,311		1,522		3(b)	(108)(c)	13,271
		545(e)		(2)(d)
Fiscal year ended April 28, 2023	6,583		4,779		39(b)	(63)(c)	11,311
				1(d)	(27)(e)

(a) Primarily consists of uncollectible accounts written off, less recoveries.

(b) Reflects the impact from acquisitions.

(d) Primarily reflects the effects of currency fluctuations.

(e) Primarily reflects the impacts from tax rate changes.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.